Illumina, Inc. (NASDAQ:ILMN) insider Francis A. Desouza sold 3,000 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $293.33, for a total transaction of $879,990.00. Following the transaction, the insider now owns 69,404 shares in the company, valued at $20,358,275.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:ILMN opened at $302.69 on Friday. The company has a current ratio of 2.46, a quick ratio of 2.24 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $44.09 billion, a price-to-earnings ratio of 75.67, a PEG ratio of 2.00 and a beta of 1.11. Illumina, Inc. has a 1-year low of $207.51 and a 1-year high of $372.61.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.26. The company had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. Illumina had a net margin of 21.09% and a return on equity of 27.10%. Illumina’s revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.11 EPS. Equities analysts expect that Illumina, Inc. will post 5.75 EPS for the current fiscal year.

A number of equities analysts recently weighed in on ILMN shares. Piper Jaffray Companies boosted their price target on shares of Illumina to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 2nd. BidaskClub lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. UBS Group started coverage on shares of Illumina in a research report on Tuesday, October 9th. They set a “neutral” rating and a $340.00 price target on the stock. ValuEngine lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Finally, Deutsche Bank boosted their price target on shares of Illumina to $350.00 and gave the stock a “buy” rating in a research report on Friday, October 12th. Four research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $337.88.

A number of large investors have recently bought and sold shares of ILMN. Moneta Group Investment Advisors LLC boosted its holdings in Illumina by 2,670.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock valued at $107,000 after purchasing an additional 9,345 shares during the last quarter. Highstreet Asset Management Inc. purchased a new stake in shares of Illumina in the 3rd quarter valued at approximately $112,000. Ancora Advisors LLC purchased a new stake in shares of Illumina in the 3rd quarter valued at approximately $145,000. Belpointe Asset Management LLC purchased a new stake in shares of Illumina in the 3rd quarter valued at approximately $155,000. Finally, SRS Capital Advisors Inc. purchased a new stake in shares of Illumina in the 3rd quarter valued at approximately $157,000. Institutional investors own 88.91% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/francis-a-desouza-sells-3000-shares-of-illumina-inc-ilmn-stock-2/2729523.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: Does the discount rate affect the economy?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.